Research Articles
- Reduction in methamphetamine induced sensitization and reinstatement after combined pergolide plus ondansetron treatment during withdrawal – View
- Heterogeneity of Stimulant Dependence – View
- Pharmacologically-mediated reactivation and reconsolidation blockade of the psychostimulant-abuse circuit – View
- Preclinical pharmacology of amphetamine – View
- Modafinil for the treatment of attention-deficit-hyperactivity disorder –View
- Polymorphism in the serotonin transporter gene and response to treatment in African American cocaine and alcohol-abusing individuals – View
- Corrigendum to “Item banks for substance use from the
Patient-Reported Outcomes Measurement Information System
(PROMIS®): Severity of use and positive appeal of use” – View - Long-acting injectable naltrexone for the treatment of alcohol dependence – View
- The Hepatitis C-Alcohol Reduction Treatment (Hep ART) intervention – View
- An Item Response Theory Modeling of Alcohol and Marijuana Dependences – View
- Treatments for Alcohol Dependence – Rethinking the Role of Comorbidity and Clinical Subtypes – View
- Problem Drinking and Low-Dose Naltrexone-Assisted Opioid Detoxification – View
- An Integrated Alcohol Abuse and Medical Treatment Model for Patients with Hepatitis C – View
- Genome-Wide Meta-Analysis of Longitudinal Alcohol Consumption Across Youth and Early Adulthood – View
- A Randomized Controlled Trial of an Integrated Alcohol Reduction Intervention in Patients With Hepatitis C Infection – View
- Hot Genes in Schizophrenia: How Clinical Datasets Could Help to Refine their Role – View
- Effectiveness and Tolerability of Switching to Aripiprazole Once Monthly from Antipsychotic Polypharmacy and/or Other Long Acting Injectable Antipsychotics for Patients with Schizophrenia in Routine Practice – View
- Clinical Benefit and Utility of Switching to Aripiprazole Once Monthly in Patients with Antipsychotic Polypharmacy or Long Acting Injectable Antipsychotics for Patients with Schizophrenia in Routine Practice – View
- Consideration of Long-Acting Injectable Antipsychotics for Polypharmacy Regimen in the Treatment of Schizophrenia: Put It on the Table or Not? – View
- Exploring Hidden Issues in the Use of Antipsychotic Polypharmacy in the Treatment of Schizophrenia – View
- Hot genes in schizophrenia: case-control, pharmaco-genetics and exploratory analyses in two independent samples – View
- Influence of TPH2 variants on diagnosis and response to treatment in patients with major depression, bipolar disorder and schizophrenia –View
- Usefulness of long-acting injectable risperidone during 12-month maintenance therapy of bipolar disorder – View
- Effect of the Dysbindin Gene on Antimanic Agents in Patients with Bipolar I Disorder – View
- Influence of BDNF Variants on Diagnosis and Response to Treatment in Patients with Major Depression, Bipolar Disorder and Schizophrenia – View
- Safety and Tolerability of Lamotrigine – Results From 12 Placebo-Controlled Clinical Trials and Clinical Implications – View
- Abelson Helper Integration Site-1 Gene Variants on Major Depressive Disorder and Bipolar Disorder – View
- Epistatic Interactions between CREB and CREM Variants in Affective Disorder – View
- A 13-Week, Randomized Double-Blind, Placebo-Controlled, Cross-Over Trial of Ziprasidone in Bipolar Spectrum Disorder – View
- The Impact of a Single Nucleotide Polymorphism in SIGMAR1 on Depressive Symptoms in Major Depressive Disorder and Bipolar Disorder – View
- Neuroplasticity, Neurotransmission and Brain-Related Genes in Major Depression and Bipolar Disorder – View
- Citalopram for Acute and Preventive Efficacy in Bipolar Depression (CAPE-BD) – View
- Association of the trace amine associated receptor 6 (TAAR6) gene with schizophrenia and bipolar disorder in a Korean case control sample – View
- Influence of TPH2 variants on diagnosis and response to treatment in patients with major depression, bipolar disorder and schizophrenia – View
- Case–control association study of 14 variants of CREB1, CREBBP and CREM on diagnosis and treatment outcome in major depressive disorder and bipolar disorder – View
- Case-control association study of 36 single-nucleotide polymorphisms within 10 candidate genes for major depression and bipolar disorder – View
- A Randomized, Double-blind, Placebo-controlled Trial of Augmentation With an Extended Release Formulation of Methylphenidate in Outpatients With Treatment-Resistant Depression – View
- Transdermal Selegiline – The New Generation of Monoamine Oxidase Inhibitors – View
- Fatigue as a core symptom in major depressive disorder_ overview and the role of bupropion – View
- Heat-shock protein-70 genes and response to antidepressants in major depression – View
- Paroxetine: current status in psychiatry – View
- Recent Advances in Post-stroke Depression – View
- Selegiline transdermal system in major depressive disorder – View
- A case of transient hallucination with ropinirole augmentation
antidepressant in a patient with treatment-resistant depression – View - Aripiprazole in the Treatment of Depressive and Anxiety Disorders – View
- Does minocycline have antidepressant effect – View
- Does Neurotropin-3 have a therapeutic implication in major depression – View
- Paroxetine safety and tolerability issues – View
- Triple Reuptake Inhibitors: A Premise and Promise – View
- Triple Reuptake Inhibitors: The Next Generation of Antidepressants – View
- Atypical Depression A Comprehensive Review – View
- Effectiveness of antidepressant treatments in pre-menopausal versus post-menopausal women – View
- History of depressive and/or anxiety disorders as a predictor of treatment response – View
- Milnacipran: Beyond a Role of Antidepressant – View
- Thyroid hormones affect recovery from depression during antidepressant treatment – View
- Paroxetine mesylate: comparable to paroxetine hydrochloride – View
- Quetiapine XR: Current status for the treatment of major depressive disorder – View
- TAAR6 variations possibly associated with antidepressant response and suicidal behavior – View
- Aripiprazole as Adjunctive Therapy for Patients with Major Depressive Disorder – View
- Escitalopram for the treatment of major depressive disorder in youth – View
- Influence of BDNF Variants on Diagnosis and Response to Treatment in Patients with Major Depression, Bipolar Disorder and Schizophrenia – View
- Influence of GRIA1, GRIA2 and GRIA4 polymorphisms on diagnosis and response to treatment in patients with major depressive disorder – View
- Influence of TPH2 variants on diagnosis and response to treatment in patients with major depression, bipolar disorder and schizophrenia – View
- A 6 Week Randomized Double-Blind Placebo-Controlled Trial of Ziprasidone for the Acute Depressive Mixed State – View
- Case–control association study of 14 variants of CREB1, CREBBP and CREM on diagnosis and treatment outcome in major depressive disorder and bipolar disorder – View
- Mixed depression: A study of its phenomenology and relation to treatment response – View
- Selegiline transdermal system in major depressive disorder – View
- A Randomized Controlled Trial of the Efficacy and Safety of Lisdexamfetamine Dimesylate as Augmentation Therapy in Adults With Residual Symptoms of Major Depressive Disorder After Treatment With Escitalopram – View
- A review of current evidence for vilazodone in major depressive disorder – View
- Atypical Antipsychotic Augmentation Strategies in the Context of Guideline-based Care for the Treatment of Major Depressive Disorder – View
- Case-control association study of 36 single-nucleotide polymorphisms within 10 candidate genes for major depression and bipolar disorder – View
- Clinical Issues in Use of Atypical Antipsychotics for Depressed Patients – View
- Investigation of possible epistatic interactions between GRIA2 and GRIA4 variants on clinical outcomes in patients with major depressive disorder – View
- Oxidative nitrosative stress and antidepressants: Targets for novel antidepressants – View
- Predictors of relapse in patients with major depressive disorder in a 52-week, fixed dose, double blind, randomized trial of selegiline transdermal system (STS) – View
- Second-generation antipsychotics in the treatment of major depressive disorder: current evidence – View
- Sensitivity of cognitive tests in four cognitive domains in discriminating MDD patients from healthy controls: a meta-analysis – View
- A review of current evidence for acetyl-L-carnitine in the treatment of depression – View
- Abelson Helper Integration Site-1 Gene Variants on Major Depressive Disorder and Bipolar Disorder – View
- Aripiprazole augmentation for major depressive disorder: dosing patterns in a naturalistic treatment setting – View
- Efficacy and safety of selegiline transdermal system (STS) for the atypical subtype of major depressive disorder – View
- Epistatic Interactions between CREB and CREM Variants in Affective Disorder – View
- Lack of influence of rs4680 (COMT) and rs6276 (DRD2) on diagnosis and clinical outcomes in patients with major depression – View
- Quetiapine Augmentation for Depression: Dosing Pattern in Routine Practice – View
- Usefulness of the Patient Health Questionnaire-9 for Korean Medical Students – View
- Vortioxetine: a meta-analysis of 12 short-term, randomized, placebo-controlled clinical trials for the treatment of major depressive disorder – View
- Vilazodone for the Treatment of Major Depressive Disorder: Focusing on Its Clinical Studies and Mechanism of Action – View
- Characteristics of neurocognitive functions in mild cognitive impairment with depression – View
- Genome-wide association study of antidepressant response: Involvement of the inorganic cation transmembrane transporter activity pathway – View
- Second Generation Antipsychotics in the Treatment of Major Depressive Disorder: An Update – View
- Vilazodone for the Treatment of Depression: An Update – View
- A Korean validation study of the Clinically Useful Anxiety Outcome Scale: Comorbidity and differentiation of anxiety and depressive disorders – View
- Adjunctive Brexpiprazole as a Novel Effective Strategy for Treating Major Depressive Disorder – View
- Measurement-based Treatment of Residual Symptoms Using Clinically Useful Depression Outcome Scale – View
- The Impact of a Single Nucleotide Polymorphism in SIGMAR1 on Depressive Symptoms in Major Depressive Disorder and Bipolar Disorder – View
- A Pharmacogenomic-based Antidepressant Treatment for Patients with Major Depressive Disorder – View
- Neuroplasticity, Neurotransmission and Brain-Related Genes in Major Depression and Bipolar Disorder – View
- Sickness absence indicating depressive symptoms of working population in South Korea – View
- Erratum: Correction of Acknowledgements Second Generation Antipsychotics in the Treatment of Major Depressive Disorder – View
- Genes Involved in Neurodevelopment, Neuroplasticity and Major Depression: No Association for CACNA1C, CHRNA7 and MAPK1 – View
- Increased Plasma Complement Factor H is associated with Geriatric Depression – View
- Reduced CXCL1/GRO chemokine plasma levels are a possible biomarker of elderly depression – View
- The Potential Utility of Aripiprazole Augmentation for Major Depressive Disorder with Mixed Features Specifier – View
- Corrigendum: A Pharmacogenomic-based Antidepressant Treatment for Patients with Major Depressive Disorder – View
- Reduced plasma Fetuin‐A is a promising biomarker of depression in the elderly – View
- Additional Reduction of Residual Symptoms with Aripiprazole Augmentation in the Patients with Partially Remitted Major Depressive Disorder – View
- Outpatient intravenous ketamine for the treatment of complex regional pain – View
- Synaptic Dysfunction in Depression – View
- Antidepressant Efficacy of Ketamine in Treatment-Resistant Major Depression – View
- Randomized Controlled Crossover Trial of Ketamine in Obsessive Compulsive Disorder – View
- A single infusion of ketamine improves depression scores in patients with anxious bipolar depression – View
- Ketamine: 50 Years of Modulating the Mind – View
- A Consensus Statement on the Use of Ketamine in the Treatment of Mood Disorders – View
- Considerations on the Off-label Use of Ketamine – View
- Efficacy of Intravenous Ketamine for Treatment of Chronic Posttraumatic Stress Disorder – View
- 7 Intravenous Ketamine Infusions for Neuropathic Pain Management – View
- The Effect of a Single Dose of Intravenous Ketamine on Suicidal Ideation – View
- Intravenous Ketamine Relieves Pain and Depression After Traumatic Suicide Attempts – View
- The effect of intravenous, intranasal, and oral ketamine in mood disorders – View
- Ketamine for the treatment of mental health and substance use disorders: Comprehensive systematic review – View
- A genetic association study of the mu opioid receptor and severe opioid dependence – View
- Nicotine dependence and treatment outcome among African American cocaine-dependent patients – View
- Extended vs Short-term Buprenorphine-Naloxone for Treatment of Opioid-Addicted Youth A Randomized Trial – View
- Very low dose naltrexone addition in opioid detoxification: a randomized, controlled trial – View
- Alterations in tryptophan and purine metabolism in cocaine addiction: a metabolomic study – View
- The construct and measurement equivalence of cocaine and opioid dependences – View
- The high prevalence of substance use disorders among recent MDMA users compared with other drug users: Implications for intervention – View
- Buprenorphine Implants for Treatment of Opioid Dependence – View
- HIV Risk Behavior in Treatment-Seeking Opioid-Dependent Youth – View
- Reduced Cannabis Use After Low-Dose Naltrexone Addition to Opioid Detoxification – View
- A National Epidemic of Unintentional Prescription Opioid Overdose Deaths: How Physicians Can Help Control It – View
- Problem Drinking and Low-Dose Naltrexone-Assisted Opioid Detoxification – View
- Predictors of attrition with buprenorphine/naloxone treatment in opioid dependent youth – View
- The Combination Very Low-Dose Naltrexone–Clonidine in the Management of Opioid Withdrawal – View
- Buprenorphine implants for treatment of opioid dependence – View
- Opioid use affects antioxidant activity and purine metabolism: preliminary results – View
- Management of Fibromyalgia – View
- Non-prescribed use of pain relievers among adolescents in the United States –View
- Serotonin-Norepinephrine Reuptake Inhibitors for Pain Control: Premise and Promise – View
- Does Pregabalin Have Neuropsychotropic Effects: A Short Perspective – View
- An Item Bank for Abuse of Prescription Pain Medication from the Patient-Reported Outcomes Measurement Information System (PROMISVR) – View
- High and Low-Structure Treatments for Substance Dependence: Role of Learned Helplessness – View
- Relationship of serum prolactin with severity of drug use and treatment outcome in cocaine dependence – View
- Relationship of disinhibition and aggression to blunted prolactin response to meta-chlorophenylpiperazine in cocaine-dependent patients – View
- A Randomized, Controlled, Trial of Controlled Release Paroxetine in Fibromyalgia – View
- Infrequent Illicit Methadone Use Among Stimulant-Using Patients in Methadone Maintenance Treatment Programs – View
- Selegiline transdermal system: Current awareness and promise – View
- Telephone Enhancement of Long-term Engagement (TELE) in Continuing Care for Substance Abuse Treatment: A NIDA Clinical Trials Network (CTN) Study – View
- Delirium: Where Do We Stand? – View
- Paroxetine for Patients with Undifferentiated Somatoform Disorder – View
- Potential role of pregabalin in the treatment of lithium-induced tremor – View
- The implementation of Buprenorphine/Naloxone in College Health Practice – View
- Venlafaxine versus Mirtazapine in the Treatment of Undifferentiated Somatoform Disorder – View
- Duloxetine: An emerging evidence for fibromyalgia – View
- Investigation of an Epistastic Effect Between a Set of TAAR6 and HSP-70 Genes Variations and Major Mood Disorders – View
- Pharmacological treatment of chronic fatigue syndrome: focusing on the role of antidepressants – View
- Psychometric Properties of the PHQ-15 for Measuring the Somatic Symptoms of Psychiatric Outpatients – View
- The impact of the CONSORT statement on reporting of randomized clinical trials in psychiatry – View
- No influence of SLC6A3 40 base VNTR polymorphism on the response to risperidone – View
- Association of sedative–hypnotic medications with suicidality – View
- Association of chronic divalproex sodium use and brain atrophy in Alzheimer’s disease – View
- Genes, Environments, and Developmental Research: Methods for a Multi-Site Study of Early Substance Abuse – View
- Safety of Selegiline Transdermal System in Clinical Practice: Analysis of Adverse Events From Postmarketing Exposures – View
- Dilemma for enhancing psychiatrists’ adherence to guideline (evidence)-based practice – View
- Item banks for substance use from the Patient-Reported Outcomes Measurement Information System (PROMIS®): Severity of use and positive appeal of use – View
- Substance Use Outcomes of an Integrated HIV–Substance Use Treatment Model Implemented by Social Workers and HIV Medical Providers – View
- Updates on Preclinical and Translational Neuroscience of Mood Disorders A Brief Historical Focus on Ketamine for the Clinician – View
- Comparative efficacy and acceptability of pharmacological interventions for the treatment and prevention of delirium – View
- Possible Modulatory Role of ARC Gene Variants in Mood Disorders – View
- Polymorphism in the serotonin transporter gene and response to treatment in African American cocaine and alcohol-abusing individuals – View
- The relationship between nicotine dependence and addiction severity amongst cocaine abusers – View
- Changes in Tobacco Smoking Following Treatment for Cocaine Dependence – View
- Psychotic Symptoms in Patients with Medical Disorders – View
- Asenapine, Blonanserin, Iloperidone, Lurasidone, and Sertindole_ Distinctive Clinical Characteristics of 5 Novel Atypical Antipsychotics – View
- Guidance for switching from off-label antipsychotics to pimavanserin for Parkinson’s disease psychosis: an expert consensus – View
- ZNF804A Gene Variants Have a Cross-diagnostic Influence on Psychosis and Treatment Improvement in Mood Disorders – View
- Extended-release formulation of venlafaxine in the treatment of post-traumatic stress disorder – View
- Pregabalin augmentation of antidepressants in patients with accident-related posttraumatic stress disorder: an open label pilot study – View
- The potential role of atypical antipsychotics for the treatment of posttraumatic stress disorder – View
- Relationship Between Tobacco Smoking and Positive and Negative Symptoms in Schizophrenia – View
- Association of the trace amine associated receptor 6 (TAAR6) gene with schizophrenia and bipolar disorder in a Korean case control sample – View
- Manganese superoxide dismutase (MnSOD: Ala–9Val) gene polymorphism may not be associated with schizophrenia and tardive dyskinesia – View
- Dysbindin gene (DTNBP1) and schizophrenia in Korean population – View
- Armodafinil as Adjunctive Therapy in Adults With Cognitive Deficits Associated With Schizophrenia – View
- Predictors of Early Worsening after Switch to Aripiprazole A Randomized, Controlled, Open-Label Study – View
- A retrospective comparison of BMI changes and the potential risk factors among schizophrenic inpatients treated with aripiprazole, olanzapine, quetiapine or risperidone – View
- Aripiprazole treatment for patients with schizophrenia_ from acute treatment to maintenance treatment – View
- Influence of BDNF Variants on Diagnosis and Response to Treatment in Patients with Major Depression, Bipolar Disorder and Schizophrenia – View
- Case–control association study for 10 genes in patients with schizophrenia: influence of 5HTR1A variation rs10042486 on schizophrenia and response to antipsychotics – View
- Influence of GRIA1, GRIA2 and GRIA4 polymorphisms on diagnosis and response to antipsychotic treatment in patients with schizophrenia – View
- Paliperidone A Review of Clinical Trial Data and Clinical Implications – View
- Possible influence of CREB1, CREBBP and CREM variants on diagnosis and treatment outcome in patients with schizophrenia – View
- Schizophrenia relapse and the clinical usefulness of once-monthly aripiprazole depot injection – View
- CACNA1C gene and schizophrenia_ a case–control and pharmacogenetic study – View
- The Influence of AHI1 Variants on the Diagnosis and Treatment Outcome in Schizophrenia – View
- Comparison between long-acting injectable aripiprazole versus paliperidone palmitate in the treatment of schizophrenia_ systematic review and indirect treatment comparison – View
- Genetic Variants Within Key Nodes of the Cascade of Antipsychotic Mechanisms: Effects on Antipsychotic Response and Schizophrenia Psychopathology in a Naturalistic Treatment Setting in Two Independent Korean – View
- Genetic Variants Within Molecular Targets of Antipsychotic Treatment_ Effects on Treatment Response, Schizophrenia Risk, and Psychopathological Features – View
- Investigational dopamine antagonists for the treatment of schizophrenia – View
- Hot Genes in Schizophrenia: How Clinical Datasets Could Help to Refine their Role – View
- Effectiveness and Tolerability of Switching to Aripiprazole Once Monthly from Antipsychotic Polypharmacy and/or Other Long Acting Injectable Antipsychotics for Patients with Schizophrenia in Routine Practice – View
- Clinical Benefit and Utility of Switching to Aripiprazole Once Monthly in Patients with Antipsychotic Polypharmacy or Long Acting Injectable Antipsychotics for Patients with Schizophrenia in Routine Practice – View
- Consideration of Long-Acting Injectable Antipsychotics for Polypharmacy Regimen in the Treatment of Schizophrenia: Put It on the Table or Not? – View
- Exploring Hidden Issues in the Use of Antipsychotic Polypharmacy in the Treatment of Schizophrenia – View
- Hot genes in schizophrenia: case-control, pharmaco-genetics and exploratory analyses in two independent samples – View
- Influence of TPH2 variants on diagnosis and response to treatment in patients with major depression, bipolar disorder and schizophrenia – View
- Relationship Between Tobacco Smoking and Positive and Negative Symptoms in Schizophrenia – View
- Tobacco smoking as a chronic disease: notes on prevention and treatment – View
- Differences in platelet serotonin transporter sites between African-American tobacco smokers and non-smokers – View
- The Genetic Determinants of Smoking – View
- The relationship between nicotine dependence and addiction severity amongst cocaine abusers – View
- Changes in Tobacco Smoking Following Treatment for Cocaine Dependence – View
- Short-, intermediate-, and long-term outcomes of Pennsylvania’s continuum of tobacco education pilot project – View
Don't delay the care you need.
Open 7-days a week with same-day appointments.